Quisinostat 2HCl

CAS No. 875320-31-3

Quisinostat 2HCl( —— )

Catalog No. M17639 CAS No. 875320-31-3

Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 116 In Stock
10MG 204 In Stock
25MG 314 In Stock
50MG 411 In Stock
100MG 593 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Quisinostat 2HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay.
  • Description
    Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.(In Vitro):JNJ-26481585 inhibits HDAC isozymes in vitro.JNJ-26481585 (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.JNJ-26481585 has broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis.(In Vivo):JNJ-26481585 (40 mg/kg; p.o.; once daily, for 3 days) as a potent HDAC1 inhibitor p21waf1,cip1 ZsGreen tumors in vivo.JNJ-26481585 induces continuous H3 acetylation in tumor tissue in vivo.JNJ-26481585 (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts.
  • In Vitro
    JNJ-26481585 inhibits HDAC isozymes in vitro.JNJ-26481585 (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells.JNJ-26481585 has broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis. Western Blot Analysis Cell Line:Human A2780 ovarian carcinoma cells Concentration:30 nM, 100 nM, 300 nM, 1000 nM Incubation Time:24 hours Result:Induced H3 and H4 acetylation at concentrations as low as 30 to 100 nM.
  • In Vivo
    JNJ-26481585 (40 mg/kg; p.o.; once daily, for 3 days) as a potent HDAC1 inhibitor p21waf1,cip1 ZsGreen tumors in vivo.JNJ-26481585 induces continuous H3 acetylation in tumor tissue in vivo.JNJ-26481585 (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts. Animal Model:NMRI nude mice, with HCT116 colon carcinoma cells xenografts Dosage:10 mg/kg Administration: Intraperitoneal injection, once daily, for 14 days Result:Strongly inhibited the growth of large pre-established HCT116 colon xenografts.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Retinoid Receptor
  • Recptor
    HDAC1| HDAC10| HDAC11| HDAC2| HDAC4
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    875320-31-3
  • Formula Weight
    467.39
  • Molecular Formula
    C21H28Cl2N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 31.25 mg/mL (66.86 mM)
  • SMILES
    Cl.Cl.CN1C=C(CNCC2CCN(CC2)C2=NC=C(C=N2)C(=O)NO)C2=CC=CC=C12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CD2665

    CD2665 is an antagonist of RAR-beta/gamma (Ki: 110 nM and 306 nM for RARγ and RARβ).

  • PA452

    PA452 is a retinoic X receptor (RXR) specific antagonist. PA452 suppresses the effect of Retinoic acid (RA) on Th1/Th2 development.

  • Fenretinide

    Fenretinide (4-HPR) is a synthetic retinoid deriverative. 4-HBR is shown to exhibit binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.